Colossal, values the Dallas-based startup at a staggering $10.2 billion. Besides making it the first startup founded in Texas ...

Rice plants can deal with the heat during the day, but when the sun goes down, they need to chill out. Developing rice with ...

If corn was ever jealous of soybean's relationship with nitrogen-fixing bacteria, advancements in gene editing could one day even the playing field. A recent study shows that gene-edited bacteria can ...

CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-based medicines with a market capitalization of $3.45 billion, stands at a critical juncture as it navigates ...

Researchers at the Broad Institute of MIT and Harvard have developed a gene-editing treatment for prion disease that extends lifespan by about 50 percent in a mouse model of the fatal ...

In BlueAllele Corp. v. Intellia Therapeutics, Inc., 2024 U.S. Dist. Lexis 222094 (D. Del. Dec. 9, 2024)1, the District of ...

CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

UK ministers are pressing ahead with legislation to adopt gene editing technology despite warnings from Brussels that it ...

Editas Medicine (EDIT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Yanan Zhu ...

Researchers have developed a gene-editing treatment for prion disease that extends lifespan by about 50 percent in a mouse model of the fatal neurodegenerative condition. The treatment ...

The biotech plans to use the funding to advance clinical testing of an epigenetic silencing therapy it hopes could treat ...

The UK’s plans to adopt the latest gene editing technology face delays over fears they will clash with EU law if Downing ...